Dyne Therapeutics Inc Asset Resilience Ratio
Dyne Therapeutics Inc asset resilience ratio. Dyne Therapeutics Inc (DYN) has an Asset Resilience Ratio of 20.28% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See DYN defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Dyne Therapeutics Inc (2007–2025)
Asset resilience ratio of Dyne Therapeutics Inc from 2007 to 2025. This chart shows how Dyne Therapeutics Inc's Asset Resilience Ratio has changed over time. Read Dyne Therapeutics Inc (DYN) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Dyne Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Dyne Therapeutics Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $219.05 Million | 20.28% |
| Total Liquid Assets | $219.05 Million | 20.28% |
Asset Resilience Insights
- Good Liquidity Position: Dyne Therapeutics Inc maintains a healthy 20.28% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Dyne Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Dyne Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Dyne Therapeutics Inc Asset Resilience Ratio by Year (2007–2025)
Dyne Therapeutics Inc asset resilience ratio by year from 2007 to 2025. The table below shows the annual Asset Resilience Ratio data for Dyne Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 18.30% | $217.19 Million | $1.19 Billion | -11.62pp |
| 2024-12-31 | 29.92% | $206.82 Million | $691.23 Million | +29.03pp |
| 2023-12-31 | 0.89% | $1.47 Million | $165.08 Million | -26.48pp |
| 2022-12-31 | 27.38% | $83.86 Million | $306.32 Million | -13.91pp |
| 2021-12-31 | 41.29% | $175.75 Million | $425.66 Million | +28.70pp |
| 2020-12-31 | 12.58% | $44.46 Million | $353.33 Million | +12.31pp |
| 2017-12-31 | 0.27% | $32.00 Million | $11.77 Billion | -0.72pp |
| 2016-12-31 | 1.00% | $130.00 Million | $13.05 Billion | +0.13pp |
| 2015-12-31 | 0.87% | $100.00 Million | $11.54 Billion | +0.17pp |
| 2014-12-31 | 0.69% | $78.00 Million | $11.23 Billion | +0.22pp |
| 2013-12-31 | 0.47% | $25.00 Million | $5.29 Billion | +0.19pp |
| 2012-12-31 | 0.29% | $13.00 Million | $4.54 Billion | -1.39pp |
| 2011-12-31 | 1.67% | $69.00 Million | $4.13 Billion | +0.61pp |
| 2010-12-31 | 1.06% | $106.00 Million | $10.01 Billion | +0.35pp |
| 2009-12-31 | 0.71% | $78.00 Million | $10.95 Billion | +0.10pp |
| 2008-12-31 | 0.61% | $87.00 Million | $14.21 Billion | -0.17pp |
| 2007-12-31 | 0.79% | $104.00 Million | $13.22 Billion | -- |
About Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal mus… Read more